GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (FRA:1OT) » Definitions » Equity-to-Asset

Ovid Therapeutics (FRA:1OT) Equity-to-Asset : 0.60 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Ovid Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €72.02 Mil. Ovid Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was €121.08 Mil. Therefore, Ovid Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.60.

The historical rank and industry rank for Ovid Therapeutics's Equity-to-Asset or its related term are showing as below:

FRA:1OT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.58   Med: 0.86   Max: 0.97
Current: 0.6

During the past 9 years, the highest Equity to Asset Ratio of Ovid Therapeutics was 0.97. The lowest was 0.58. And the median was 0.86.

FRA:1OT's Equity-to-Asset is ranked worse than
56.25% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs FRA:1OT: 0.60

Ovid Therapeutics Equity-to-Asset Historical Data

The historical data trend for Ovid Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovid Therapeutics Equity-to-Asset Chart

Ovid Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.87 0.58 0.92 0.85 0.61

Ovid Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.81 0.81 0.61 0.60

Competitive Comparison of Ovid Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Ovid Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovid Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's Equity-to-Asset falls into.



Ovid Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Ovid Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=80.51/132.073
=0.61

Ovid Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=72.017/121.084
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ovid Therapeutics  (FRA:1OT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Ovid Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovid Therapeutics (FRA:1OT) Business Description

Traded in Other Exchanges
Address
441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics (FRA:1OT) Headlines

No Headlines